January 18, 2017 9:59 PM ET

Pharmaceuticals

Company Overview of Intersect ENT, Inc.

Company Overview

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The company is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting; and NOVA, a steroid releasing implant to fit the ostia, or openings, of the dependent sinuses following enlargement of the sinuses. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, I...

1555 Adams Drive

Menlo Park, CA 94025

United States

Founded in 2003

275 Employees

Phone:

650-641-2100

Key Executives for Intersect ENT, Inc.

Chief Executive Officer, President and Director
Age: 46
Total Annual Compensation: $442.4K
Chief Financial Officer
Age: 58
Total Annual Compensation: $357.9K
Chief Operating Officer and Vice President of R&D & Operations
Age: 54
Total Annual Compensation: $324.1K
Vice President of Clinical Affairs
Age: 46
Total Annual Compensation: $263.7K
Compensation as of Fiscal Year 2015.

Intersect ENT, Inc. Key Developments

Intersect ENT, Inc. Provides Sales Guidance for the Fourth Quarter and Year Ended December 31, 2016 and for the First Quarter and Full Year of 2017

Intersect ENT, Inc. provided sales guidance for the fourth quarter and year ended December 31, 2016 and for the first quarter and full year of 2017. For the fourth quarter, revenue is expected to be in the range of $24.0 million to $24.2 million. For the full year 2016 revenue is expected to be in the range of $78.5 million to $78.7 million. The company forecasts 2017 revenue of approximately $87-89 million and first quarter revenue of $19 million - $19.5 million.

Intersect ENT, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 02:30 PM

Intersect ENT, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 02:30 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Lisa D. Earnhardt, Chief Executive Officer, President and Director.

Intersect ENT, Inc. Presents at 28th Annual Piper Jaffray Healthcare Conference, Nov-29-2016 04:30 PM

Intersect ENT, Inc. Presents at 28th Annual Piper Jaffray Healthcare Conference, Nov-29-2016 04:30 PM. Venue: The Lotte New York Palace, 50th St. and Madison Avenue, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intersect ENT, Inc., please visit www.intersectent.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.